Malt Lymphoma - Pipeline Insight, 2024

This “Malt Lymphoma - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Malt Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malt Lymphoma: Understanding

Malt Lymphoma: Overview

The neoplastic proliferation of B cells in the marginal zone of lymphoid tissue gives rise to marginal zone B cell lymphomas. Mucosa-associated lymphoid tissue lymphoma or MALT lymphoma is the term used for extranodal marginal zone lymphoma referred to as MALT Lymphoma. Other commonly involved extranodal sites include other parts of the gastrointestinal tract, thyroid, salivary gland, lung, lacrimal gland, synovium, dura mater, breast, skin, and eyes.

This type of lymphoma is typically a low-grade neoplasia, characterized by a dense lymphoid infiltration that invades and destroys gastric glands and results in the so-called “lymphoepithelial lesion” which is pathognomonic for lymphoma. MALT lymphomas do not have a specific antigenic profile, the B-cells sharing the immunophenotype with marginal zone B-cells present in the spleen, Peyer’s patches and lymph nodes, so gastric lymphoma is CD20+, CD5+; CD10-, CD23- and cyclin D1..

Malt Lymphoma - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malt Lymphoma pipeline landscape is provided which includes the disease overview and Malt Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Malt Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Malt Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve in Malt Lymphoma.

This segment of the Malt Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malt Lymphoma Emerging Drugs

Tafasitamab: Incyte Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab®5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of MaltLymphoma..

Malt Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different Malt Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Malt Lymphoma

There are approx. 10+ key companies which are developing the therapies for Malt Lymphoma. The companies which have their Malt Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Incyte.

Phases

This report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Malt Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Small Molecule
• Gene Therapy
• Peptide
• Immunotherapy
• Cell Therapy

Molecule Type

Products have been categorized under various Molecule types such as

• Intravenous
• Intradermal
• Oral
• Subcutaneous
• Intramuscular

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malt Lymphoma : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malt Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malt Lymphoma drugs.

Malt Lymphoma Report Insights

• Malt Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malt Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malt Lymphoma drugs?
• How many Malt Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malt Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malt Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malt Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• MEI Pharma
• Incyte
• Genentech
• BeiGene
• Sound Biologics
• ADC Therapeutics
• Loxo Oncology

Key Products

• Zandelisib
• Tafasitamab
• Mosunetuzumab
• BGB-10188
• PSB202
• Loncastuximab tesirine
• Pirtobrutinib

This product will be delivered within 2 business days.